Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells

Journal of Neuro-Oncology

Volumn 126, Issue 3, 2016, Pages 425-431

  Kast, Richard E ^a   Ramiro, Susana ^b   Lladó, Sandra ^b   Toro, Salvador ^b   Coveñas, Rafael ^c   Muñoz, Miguel ^b  

^a IIAIGC Headquarters   (United States)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Aprepitant; Combination therapy; Glioblastoma; Ritonavir; Temozolomide

Indexed keywords

ACICLOVIR; APREPITANT; CIDOFOVIR; MARAVIROC; RITONAVIR; TEMOZOLOMIDE; ALKYLATING AGENT; ANTIEMETIC AGENT; DACARBAZINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MORPHOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IC50; ANALOGS AND DERIVATIVES; APOPTOSIS; BRAIN NEOPLASMS; DRUG EFFECTS; ENZYME IMMUNOASSAY; GLIOBLASTOMA; PATHOLOGY; TUMOR CELL CULTURE;

ANTIEMETICS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CELL PROLIFERATION; DACARBAZINE; GLIOBLASTOMA; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOENZYME TECHNIQUES; MORPHOLINES; RITONAVIR; TUMOR CELLS, CULTURED;

EID: 84956610707     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1996-6     Document Type: Article

References (46)

1. Frosina G (2015) Limited advances in therapy of glioblastoma trigger re-consideration of research policy. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2015.05.013
2. Alifieris C, Trafalis DT (2015) Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther 152:63–82
3. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20(4):450–458
4. Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT (2013) Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev 39(1):113–117
5. Coveñas R, Muñoz M (2014) Cancer progression and substance P. Histol Histopathol 29(7):881–890
6. Kast RE (2009) Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question. Clin Transl Oncol 11(7):408–410
7. Kast RE, Karpel-Massler G, Halatsch ME (2014) CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget 5(18):8052–8082
8. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Dueñas-González A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, Marosi C, McDonald K, Muñoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME (2013) A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4(4):502–530
9. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S (2000) Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82(2):480–487
10. Muñoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28(2):187–193
11. De Clercq E (2003) Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 16(4):569–596
12. Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, Vanden Houte K, Reynders M, Snoeck R, Bossens M (2009) Topical treatment of CIN 2 + by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 115(1):69–74
13. Moyo TK, Richards KL, Damania B (2010) Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma. Clin Adv Hematol Oncol 8(5):372–374
14. De Schutter T, Andrei G, Topalis D, Naesens L, Snoeck R (2013) Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med Genomics 6:18
15. Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS (2013) Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res 19(23):6473–6483
16. Liekens S, Noppen S, Gijsbers S, Sienaert R, Ronca R, Tobia C, Presta M (2015) The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget 6(7):4633–4648
17. Wang F, Yang L, Shi L, Li Q, Zhang G, Wu J, Zheng J, Jiao B (2015) Nuclear translocation of fibroblast growth factor-2 (FGF2) is regulated by karyopherin-β2 and Ran GTPase in human glioblastoma cells. Oncotarget 6(25):21468–21478
18. Wu J, Feng X, Zhang B, Li J, Xu X, Liu J, Wang X, Wang J, Tong X (2014) Blocking the bFGF/STAT3 interaction through specific signaling pathways induces apoptosis in glioblastoma cells. J Neurooncol 120(1):33–41
19. Ader I, Delmas C, Skuli N, Bonnet J, Schaeffer P, Bono F, Cohen-Jonathan-Moyal E, Toulas C (2014) Preclinical evidence that SSR128129E- a novel small-molecule multi-fibroblast growth factor receptor blocker- radiosensitises human glioblastoma. Eur J Cancer 50(13):2351–2359
20. Haley EM, Kim Y (2014) The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture. Cancer Lett 346(1):1–5
21. Lieberman-Blum SS, Fung HB, Bandres JC (2008) Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 30(7):1228–1250
22. Kast RE (2010) Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther 35(6):657–663
23. Rappa F, Cappello F, Halatsch ME, Scheuerle A, Kast RE (2013) Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells. Biochimie 95(4):782–786
24. Kast RE (2015) The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir. Chin J Cancer 34(4):161–165
25. Sato A (2015) The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. Onco Targets Ther 8:761–768
26. Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10(1):61–71
27. Liu R, Zhang L, Yang J, Zhang X, Mikkelsen R, Song S, Zhou H (2015) HIV protease inhibitors sensitize human head and neck squamous carcinoma cells to radiation by activating endoplasmic reticulum stress. PLoS One 10(5):e0125928
28. Laurent N, de Bouard S, Guillamo JS, Christov C, Zini R, Jouault H, Andre P, Lotteau V, Peschanski M (2004) Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 3(2):129–136
29. Bruening A, Jueckstock J (2015) Misfolded proteins: from little villains to little helpers in the fight against cancer. Front Oncol 5:47
30. Weiss M, Kost B, Renner-Mueller I, Wolf E, Mylonas I, Bruening A (2015) Efavirenz causes oxidative stress, endoplasmic reticulum stress, and autophagy in endothelial cells. Cardiovasc Toxicol. doi:10.1007/s12012-015-9314-2
31. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA (2007) Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13(17):5183–5194
32. Muñoz M, Coveñas R (2013) Involvement of substance P and the NK-1 receptor in cancer progression. Peptides 48:1–9
33. Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39(4):427–432
34. Nakajima Y, Tsuchida K, Negishi M, Ito S, Nakanishi S (1992) Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cAMP cascades in transfected Chinese hamster ovary cells. J Biol Chem 267(4):2437–2442
35. Takeda Y, Blount P, Sachais BS, Hershey AD, Raddatz R, Krause JE (1992) Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1, 4, 5-triphosphate and cyclic AMP second messenger responses. J Neurochem 59(2):740–745
36. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM (2009) A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109(4):1079–1086
37. Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, Kandela I, Wei C, Singhal S, Koblinski JE, Raje NS, Rosen ST, Shanmugam M (2015) Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin Cancer Res 21(5):1161–1171
38. Batchu RB, Gruzdyn OV, Bryant CS, Qazi AM, Kumar S, Chamala S, Kung ST, Sanka RS, Puttagunta US, Weaver DW, Gruber SA (2014) Ritonavir-mediated induction of apoptosis in pancreatic cancer occurs via the RB/E2F-1 and AKT pathways. Pharmaceuticals (Basel) 7(1):46–57
39. Kraus M, Mueller-Ide H, Rueckrich T, Bader J, Overkleeft H, Driessen C (2014) Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leuk Res 38(3):383–392
40. Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, Douglas SD (2010) Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS 24(18):2789–2796
41. Muñoz M, Coveñas R (2013) Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf 12(5):673–685
42. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-knowles E, Halle JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlsson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281(5383):1640–1645
43. Harford-Wright E, Lewis KM, Ghabriel MN, Vink R (2014) Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors. PLoS ONE 9(5):e97002
44. Endo T, Saijo T, Haneda E, Maeda J, Tokunaga M, Zhang MR, Kannami A, Asai H, Suzuki M, Suhara T, Higuchi M (2015) Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography. Int J Neuropsychopharmacol 18(2):pyu030
45. Bergström M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Långström B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55(10):1007–1012
46. Anthonypillai C, Sanderson RN, Gibbs JE, Thomas SA (2004) The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J Pharmacol ExpTher 308(3):912–920